SEC Form 4 · accession 0002097951-26-000001
Faeth Therapeutics, Inc. · FTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Gerry
Officer — President & PEO
Period of report
Jun 10, 2026
Accepted (ET)
Jun 12, 2026 · 9:12 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001829802
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $29.89 | Jun 10, 2026 | A | 220,000 | A | — | Jun 9, 2036 | Common Stock | 220,000 | 220,000 | D |
Explanation of responses
- F1The stock option grant was approved by the Issuer's Board of Directors on April 10, 2026, subject to stockholder approval of the 2026 Equity Incentive Plan, which approval was obtained on June 10, 2026. The exercise price reflects the closing price of the Issuer's common stock on April 10, 2026.
- F225% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the vesting commencement date, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.